Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein ...

(L to R) Corresponding author Hongbo Chi, co-first author Sujing Yuan and co-first author Renqiang Sun, PhD, PhD, St. Jude Department of Immunology. (MEMPHIS, Tenn. – March 19, 2025) Targeted ...